Thursday, July 12, 2018

KemPharm Stock Down Despite Positive Data on ADHD Candidate - Zacks.com


Zacks.com

KemPharm Stock Down Despite Positive Data on ADHD Candidate
Zacks.com
The double-blind placebo-controlled study (n=150) on KP415 was conducted on children with ADHD in the age bracket of six to 12 years. Patients having received KP415 showed a significant statistical improvement on the Swanson, Kotkin, Agler, M-Flynn ...

and more »

No comments:

Post a Comment